Genmab A/S (GEN.CO) and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead
6/17/2013 9:05:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark and Lausanne, Switzerland; June 17, 2013 – Genmab A/S (OMX: GEN) and ADC Therapeutics Sarl announced today an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. The Companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with HuMax-TAC, and now have the product ready for pre-IND preclinical development. The product will be developed for multiple cancer indications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by